Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
04 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
20 Feb 2025 According to a Verastem Oncology media release, company announced multiple oral and poster presentations, including an oral presentation of additional analyses from this trial at the Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer, to be held on March 14-17 in Seattle, Washington. Verastem will also have an exhibition booth 622 at the meeting where it will be available to discuss its ongoing cancer research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com